e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Novel targets in the molecular pathology of lung cancer and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The proteasome inhibitor bortezomib is effective against experimental malignant pleural effusion
I. Psallidas, S. Karabela, C. Moschos, A. Kollintza, P. Theodoropoulou, C. Roussos, I. Kalomenidis, G. T. Stathopoulos (Athens, Greece)
Source:
Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD
Session:
Novel targets in the molecular pathology of lung cancer and COPD
Session type:
Oral Presentation
Number:
3000
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Psallidas, S. Karabela, C. Moschos, A. Kollintza, P. Theodoropoulou, C. Roussos, I. Kalomenidis, G. T. Stathopoulos (Athens, Greece). The proteasome inhibitor bortezomib is effective against experimental malignant pleural effusion. Eur Respir J 2008; 32: Suppl. 52, 3000
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009
Systemic treatment of malignant pleural effusion
Source: Annual Congress 2005 - What's new in the pleura
Year: 2005
mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma
Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma
Year: 2011
Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer
Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Year: 2019
The therapeutic efficacy of troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Pleurodesis in the treatment of malignant pleural effusion
Source: Eur Respir J 2004; 24: Suppl. 48, 628s
Year: 2004
Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions
Source: Eur Respir J 2004; 24: 263-266
Year: 2004
Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 61s
Year: 2003
Videothoracoscopy in the treatment of malignant pleural effusions
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma
Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions
Year: 2012
Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma
Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma
Year: 2011
Diagnostic implications of telomerase activity in pleural effusions
Source: Eur Respir J 2003; 22: 422-426
Year: 2003
Results of treatment of the metastatic pleural effusion
Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions
Year: 2012
Bevacizumab-targeted therapy for malignant pleural mesothelioma
Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs
Year: 2017
Survival of lung adenocarcinoma patients with malignant pleural effusion
Source: Eur Respir J 2013; 41: 1409-1418
Year: 2013
In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control?
Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Year: 2020
Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Chemotherapy for treatment of malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004
Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion?
Source: International Congress 2017 – Pleural and mediastinal malignancies
Year: 2017
ADAM10 membrane-bound protease mediates malignant pleural mesothelioma invasiveness
Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept